To further delineate the effects of the initial tumor exposure from those resulting from therapy, we analyzed CXCR3 expression in CD8 + T cells as a surrogate marker for immunological disturbances in triple-matched samples from 136 MM patients collected at initial diagnosis after induction therapy and following high-dose melphalan treatment with autologous stem cell transplantation. The gene discussed is CD8A; the disease is neoplasm.